Isoray, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.

History

Isoray, Inc. was founded in 2003 to seek better treatments and cures for cancer through the development, sale and marketing of innovative, proprietary and clinically tested radiation therapy technology.

Mission

Isoray is dedicated to developing innovative, clinically tested products and services that lead to enhanced cancer care, improved patient outcomes and meaningful quality of life.

Vision

To improve the lives of those affected by cancer and become a leader in radiation-based cancer treatments.

Key Team

Mr. Jonathan R. Hunt (CFO & Co-Principal Financial Officer)

Mr. Mark J. Austin CPA (VP of Fin., Controller, Co-Principal Financial, Principal Accounting Officer & Sec.)

Ms. Krista Cline (Sr. Director of Operations & Corp. Sec.)

Recognition and Awards

Isoray has been the recipient of numerous awards including Best Radioactive Seed Therapy of the Decade Award, Best Radioactive Seed Therapy of the Year award, National Innovation awards and many more.